Lynne Marie Sullivan

CIK: 0001727640

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)3 (37.5%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (50.0%)

Compensation grants

Other (G, F, J, C, D, …)1 (12.5%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

SLDB

Solid Biosciences Inc.

Director

INZY

Inozyme Pharma, Inc.

Director

UBX

Unity Biotechnology, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (8 total)

SLDB
Solid Biosciences Inc.
Jun 10, 2026
Award(A)
Director Stock Option (Right to Buy)
Direct
77.5K shares-
INZY
Inozyme Pharma, Inc.
Jul 1, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
28.4K shares-
SLDB
Solid Biosciences Inc.
Jun 12, 2025
Award(A)
Director Stock Option (Right to Buy)
Direct
77.5K shares-
UBX
Unity Biotechnology, Inc.
Apr 2, 2025
Sale(S)
Direct
21.9K shares at avg. $1.03$23K
UBX
Unity Biotechnology, Inc.
Mar 28, 2025
Award(A)
Direct
65K shares-
UBX
Unity Biotechnology, Inc.
Feb 4, 2025
Sale(S)
Direct
153 shares at avg. $2.23$341.19
UBX
Unity Biotechnology, Inc.
Jan 22, 2025
Award(A)
Stock Option (Right to Buy)
Direct
150K shares-
UBX
Unity Biotechnology, Inc.
Nov 4, 2024
Sale(S)
Direct
136 shares at avg. $1.29$175.44

		Type	Shares	Price		Ownership
Jun 10, 2026	SLDB Solid Biosciences Inc.	Award(A) Director Stock Option (Right to Buy)	77,500	-	-	Direct
Jul 1, 2025	INZY Inozyme Pharma, Inc.	Disposition(D) Stock Option (Right to Buy)	28,368	-	-	Direct
Jun 12, 2025	SLDB Solid Biosciences Inc.	Award(A) Director Stock Option (Right to Buy)	77,500	-	-	Direct
Apr 2, 2025	UBX Unity Biotechnology, Inc.	Sale(S)	21,867	$1.03	$22,523	Direct
Mar 28, 2025	UBX Unity Biotechnology, Inc.	Award(A)	65,000	-	-	Direct
Feb 4, 2025	UBX Unity Biotechnology, Inc.	Sale(S)	153	$2.23	$341	Direct
Jan 22, 2025	UBX Unity Biotechnology, Inc.	Award(A) Stock Option (Right to Buy)	150,000	-	-	Direct
Nov 4, 2024	UBX Unity Biotechnology, Inc.	Sale(S)	136	$1.29	$175	Direct

1-8 of 8 transactions

About Sullivan Lynne Marie

Sullivan Lynne Marie (SEC CIK 0001727640) files insider reports with the SEC as Director of Solid Biosciences Inc. (SLDB), Director of Inozyme Pharma, Inc. (INZY) and CFO & Head of Corp. Dev. of Unity Biotechnology, Inc. (UBX).

Signal8 holds 8 ownership filings by Sullivan Lynne Marie, all Form 4s, filed between Nov 6, 2024 and Jun 11, 2026. Those filings report 8 transactions, from Nov 4, 2024 to Jun 10, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Sullivan Lynne Marie's filings is in CHARLESTOWN, MA.

Recent filings by Sullivan Lynne Marie

Jun 10, 2026: Grant or award of SLDB derivative securities (Form 4, code A).
Jul 1, 2025: Disposition to issuer transaction of INZY derivative securities (Form 4, code D).
Jun 12, 2025: Grant or award of SLDB derivative securities (Form 4, code A).
Apr 2, 2025: Open-market sale of UBX shares (Form 4, code S).
Mar 28, 2025: Grant or award of UBX shares (Form 4, code A).

Other insiders filing for Solid Biosciences Inc. (SLDB)

Ganot Ilan, Director
Brooks Gabriel, Chief Medical Officer
SMITH IAN F, Director
RA CAPITAL MANAGEMENT, L.P., 10% Owner
Nagendran Sukumar, Director
PERCEPTIVE ADVISORS LLC, Director

How to read Form 4 transaction codes